系统性红斑狼疮患者血浆miRNA-23a表达的检测及意义

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (1592 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore miR-23a expression and its clinical significance in the plasma of systemic lupus erythematosus (SLE) patients. Methods: Plasma samples from 54 SLE patients, 16 rheumatoid arthritis (RA) patients and 20 healthy controls were collected. The small RNAs in these plasma samples were isolated and reversely transcribed. Using cel-miR-39 as the external reference, the levels of miR-23a expression were detected with real-time polymerase chain reaction (PCR) method. The correlation between the levels of miR-23a expression and the clinical pathological features of SLE and biological significance of miR-23a expression in SLE were further analyzed with statistical methods. Results: Our data indicated that the levels of miR-23a expression in the plasma of SLE patients, RA patients and healthy controls were significantly different (x2=39.199, P<0.001). The level of miR-23a in the plasma of SLE patients was statistically lower than that in RA patients and healthy controls (P<0.05). The area under the ROC (receiver-operating characteristic) curve (AUC) was 0.931 for discriminating between SLE patients and normal subjects and 0.884 for discriminating between SLE and RA patients and patients. The levels of miR-23a expression were set the cutoff values of 19.22 for healthy control and 30.98 for RA patients, the diagnostic sensitivity and specificity were 74.5%, 88.9%, and 73.3%, 86.3%, respectively. The analysis of the correlation between miR-23a expression and the clinical pathological features of SLE shown that the levels of plasma miR-23a expression had positively correlated with anti-ANA titers and negatively correlated with white blood cell count (P<0.05). Conclusion: Down-regulated of miR-23a expression in plasma of SLE may be involved in the SLE disease occurrence or development and can be used as a novel potential diagnostic biomarker for SLE.

Key words： systemic lupus erythematosus microRNA miR-23a

Received: 14 September 2015

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Lulu
	FAN Chaofan
	HUANG Xixi
	GUO Gangqiang
	ZHANG Huidi
	ZHANG Lifang
	LIN Qiaoai
	XUE Xiangyang.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2016/V46/I3/168

[1] HERRMANN M, VOLL R E, KALDEN J R. Etiopathogenesis of systemic lupus erythematosus[J]. Immunol Today, 2000, 21(9): 424-426.
[2] WAKELAND E K, LIU K, GRAHAM R R, et al. Delineating the genetic basis of systemic lupus erythematosus[J].Immunity, 2001, 15(3): 397-408.
[3] ILLEI G G, TACKEY E, LAPTEVA L, et al. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity[J]. Arthritis Rheum, 2004, 50(7): 2048-2065.
[4] ROVIN B H, BIRMINGHAM D J, NAGARAJA H N, et al. Biomarker discovery in human SLE nephritis[J]. Bull NYU Hosp Jt Dis, 2007, 65(3): 187-193.
[5] LIU C C, MANZI S, AHEARN J M. Biomarkers for sys-temic lupus erythematosus: a review and perspective[J]. Curr Opin Rheumatol, 2005, 17(5): 543-549.
[6] ABULABAN K M, BRUNNER H I. Biomarkers for childhood-onset systemic lupus erythematosus[J]. Curr Rheumatol Rep, 2015, 17(1): 471.
[7] RUVKUN G. Molecular biology. Glimpses of a tiny RNA world[J]. Science, 2001, 294(5543): 797-799.
[8] BARTEL D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[9] PICASCIA A, GRIMALDI V, PIGNALOSA O, et al. Epigenetic control of autoimmune diseases: from bench to bedside[J]. Clin Immunol, 2015, 157(1):1-15.
[10] SIMPSON L J, ANSEL K M. MicroRNA regulation of lymphocyte tolerance and autoimmunity[J]. J Clin Invest,2015, 125(6): 2242-2249.
[11] HA T Y. MicroRNAs in human diseases: from autoimmune diseases to skin, psychiatric and neurodegenerative diseases[J]. Immune Netw, 2011, 11(5): 227-244.
[12] 陈阿琼, 薛向阳, 章丽和, 等. miR-16在系统性红斑狼疮血浆中的表达及意义[J]. 温州医学院学报, 2013, 43(1): 106-111.
[13] 陈芳, 陈朝生, 章慧娣, 等. 系统性红斑狼疮患者外周血B淋巴细胞中狼疮活动相关miRNA的筛选[J]. 温州医学院学报, 2013, 43(2): 26-30.
[14] CERIBELLI A, YAO B, DOMINGUEZ-GUTIERREZ P R, et al. MicroRNAs in systemic rheumatic diseases[J]. Arthritis Res Ther, 2011, 13(4): 229.
[15] QU B, SHEN N. miRNAs in the pathogenesis of systemic lupus erythematosus[J]. Int J Mol Sci, 2015, 16(5): 9557-9572.
[16] WEBER J A, BAXTER D H, ZHANG S, et al. The microRNA spectrum in 12 body fluids[J]. Clin Chem, 2010, 56(11):1733-1741.
[17] PARK N J, ZHOU H, ELASHOFF D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection[J]. Clin Cancer Res, 2009, 15(17): 5473-5477.
[18] CHEN X, BA Y, MA L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006.
[19] ZHENG D, HADDADIN S, WANG Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer[J]. Int J Clin Exp Pathol, 2011, 4(6): 575-586.
[20] PERFETTI A, GRECO S, BUGIARDINI E, et al. Plasma microRNAs as biomarkers for myotonic dystrophy type 1[J].Neuromuscul Disord, 2014, 24(6): 509-515.
[21] KJERSEM J B, IKDAHL T, LINGJAERDE O C, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatinbased treatment[J]. Mol Oncol, 2014, 8(1): 59-67.
[22] ZHANG W, SHANG T, HUANG C, et al. Plasma microRNAs serve as potential biomarkers for abdominal aortic aneurysm[J]. Clin Biochem, 2015, 48(15): 988-992.
[23] PENG P, LI Z, LIU X. Reduced Expression of miR-23a Suppresses A20 in TLR-stimulated Macrophages[J]. Inflammation, 2015, 38(5): 1787-1793.
[24] SARRION I, MILIAN L, JUAN G, et al. Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a[J]. Oxid Med Cell Longev, 2015, 2015: 792846.
[25] CAI S, CHEN R, LI X, et al. Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway[J]. Oncotarget, 2015, 6(6):3904-3917.
[26] LIN R, SAMPSON J H, LI Q J, et al. miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment[J]. Oncoimmunology, 2015, 4(3): e990803.
[27] LUO Z, FENG X, WANG H, et al. Mir-23a induces telomere dysfunction and cellular senescence by inhibiting TRF2 expression[J]. Aging Cell, 2015, 14(3): 391-399.
[28] CORTEZ M A, CALIN G A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther, 2009, 9(6): 703-711.
[29] SURYAWANSHI S, VLAD A M, LIN H M, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer[J]. Clin Cancer Res, 2013, 19(5): 1213-1224.